Table 2

 Publicly available accuracy measures of Determine Syphilis TP point-of-care test

LocationStudy designStudy sampleSample type used with POC testReference standardSensitivity (95% CI)Specificity (95% CI)
*Performance characteristics were obtained from the same study using two different reference standards.
†Performance characteristics were calculated for three different readers.
‡Calculated using diagti commands in Stata version 9 (StataCorp LP, College Station, Texas, USA).
CI, confidence interval; ELISA, enzyme-linked immunosorbent assay; FTA-ABS, fluorescent treponemal antibody; RPR, rapid plasma reagin; STI, sexually transmitted infection; TB, tuberculosis; TPHA, Treponema pallidum haemagglutination assay; TPPA, Treponema pallidum particle agglutination assay; VDRL, venereal diseases research laboratory.
Bolivia (present study)Prospective8889 pregnant womenWhole blood from finger-stickRPR, positives confirmed by TPPA91.8 (88.4 to 94.5)98.5 (98.2 to 98.8)
Brazil*†5Retrospective250 TPHA+; 300 TPHA−Stored serumTPHA only97.6 (94.6 to 98.8)97.3 (94.6 to 98.6)
98.4 (95.6 to 99.4)95.7 (92.9 to 97.7)
95.6 (93.2 to 96.2)96.3 (93.4 to 98.3)
Brazil*†5Retrospective195 VDRL and TPHA+; 300 VDRL and TPHA−Stored serumVDRL and TPHA97.9 (94.4 to 99.2)97.3 (94.6 to 98.6)
98.5 (95.1 to 99.4)95.7 (92.9 to 97.7)
96.9 (93.6 to 98.9)96.3 (93.4 to 98.3)
Brazil6Retrospective63 syphilis cases; 24 with other STD; 38 syphilis seronegativeSerumClinical evaluation, VDRL, FTA-ABS, TPHA, and ELISA93.7 (84.4 to 97.9)95.2 (86.4 to 98.7)
WHO SDI multi-country evaluation7Retrospective399 TPHA or TPPA+; 390 TPHA or TPPA−Stored serumTPHA or TPPA97.2 (95.6 to 98.8)94.1 (91.8 to 96.4)
Vietnam8Prospective291 participants: 71 syphilis cases; 92 negative cases; 128 potential cross reacting (by hepatitis A and B, HIV, malaria, pregnancy, syphilis, TB and high risk of STI acquisition)Venous whole blood, plasma and serumRPR confirmed by ELISA (FTA-ABS used to resolve discordant confirmatory results)100 (95.0 to 100.0)‡98.6 (96.0 to 99.7)